Last reviewed · How we verify

Conventional fecal microbiota transplantation — Competitive Intelligence Brief

Conventional fecal microbiota transplantation (Conventional fecal microbiota transplantation) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microbiota-based therapeutic. Area: Gastroenterology / Infectious Disease.

phase 3 Microbiota-based therapeutic Gastroenterology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Conventional fecal microbiota transplantation (Conventional fecal microbiota transplantation) — University of Pecs. Fecal microbiota transplantation restores a healthy gut microbiome by introducing diverse bacterial communities from a donor to treat dysbiosis-related conditions.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Conventional fecal microbiota transplantation TARGET Conventional fecal microbiota transplantation University of Pecs phase 3 Microbiota-based therapeutic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Microbiota-based therapeutic class)

  1. University of Pecs · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Conventional fecal microbiota transplantation — Competitive Intelligence Brief. https://druglandscape.com/ci/conventional-fecal-microbiota-transplantation. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: